论文部分内容阅读
目的探讨糖皮质激素和长效β2受体激动剂联合吸入与单独吸入糖皮质激素治疗支气管哮喘(哮喘)的疗效及对肺功能的影响。方法对首次本院就诊的6～14岁符合哮喘诊断标准的临床发作哮喘患儿76例,随机分为观察组40例和对照组36例。观察组予糖皮质激素与长效β2受体激动剂联合吸入治疗,对照组仅予单纯糖皮质激素吸入治疗。治疗6、12个月测定其肺功能指标,并观察临床疗效,进行对比并行统计学分析。结果观察组随访35例,对照组随访32例,治疗6个月观察组肺功能改善情况及临床控制率优于对照组(Pa<0.05),治疗12个月2组疗效相近(Pa>0.05)。结论糖皮质激素与长效β2受体激动剂联合吸入治疗6岁以上哮喘在治疗阶段临床控制率及肺功能改善优于单纯吸入激素,治疗12个月2组临床控制率及肺功能指标相近,主张哮喘仍以单独吸入激素治疗为主或联合治疗,临床控制后尽早改为单独吸入激素维持治疗。
Objective To investigate the effects of glucocorticoid and long-acting β2 receptor agonist combined with inhaled glucocorticoid on bronchial asthma (asthma) and its effect on lung function. Methods Sixty-six children with clinical asthma who were diagnosed as asthma at the age of 6 to 14 years were selected and randomly divided into observation group (40 cases) and control group (36 cases). The observation group was given glucocorticoid and long-acting β2 receptor agonist inhalation therapy, the control group was treated with simple glucocorticoid inhalation. Six and 12 months after treatment, the lung function indexes were measured and the clinical effects were observed. Results The observation group was followed up for 35 cases and the control group was followed up for 32 cases. The improvement of pulmonary function and clinical control rate in the observation group for 6 months were better than those for the control group (Pa 0.05) . Conclusion The combination of glucocorticoid and long-acting β2 receptor agonist inhalation for the treatment of asthma over 6 years old in the treatment phase of clinical control and pulmonary function improved better than pure inhaled hormone, 12-month treatment of two groups of clinical control and lung function indicators are similar, Advocacy of asthma is still based on inhaled hormone therapy alone or in combination, as soon as possible after clinical control to change the hormone maintenance therapy alone.